ArticleBMC complementary medicine and therapies2026
Crocin and eugenol enhance radiosensitivity in oral squamous cell carcinoma cells via apoptotic pathways and cell cycle regulation. Type of study: in vitro.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral squamous cell carcinoma (OSCC) continues to be a significant clinical challenge because of radioresistance and treatment-related toxicities. Safer radiosensitizers are urgently needed.
objectiveThis study assessed the radiosensitizing effects of crocin and eugenol on OSCC-1 cells in vitro.
methodsOSCC-1 cells were treated with crocin, eugenol, ionizing radiation, or their combinations. Cell viability (MTT assay), apoptosis (Annexin V/PI), and cell cycle distribution (PI staining) were assessed, along with transcriptional expression of Bax, Bcl-2, Caspase-3, Cyclin A, and Cyclin B measured by RT-qPCR. The effects of the combinations were analyzed using the Chou-Talalay method.
resultsBoth crocin and eugenol independently decreased OSCC cell viability and triggered apoptosis in a dose-dependent way. When used with IR, they worked together to boost cytotoxicity at moderate doses (CI < 1). Crocin caused early G1 arrest followed by G2/M accumulation, while eugenol strongly induced G2/M arrest and increased sub-G1 fractions. Molecular analysis showed activation of the intrinsic apoptotic pathway (↑Bax, ↑Caspase-3, ↓Bcl-2) and reduced levels of Cyclin A/B transcripts.
conclusionCrocin and eugenol effectively sensitize OSCC cells to IR by regulating apoptotic factors and promoting checkpoint arrest. Their favorable safety profiles and ability to enhance radiosensitivity support further in vivo studies and translational development as natural adjuncts in radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.